{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:43:09Z","timestamp":1793666589550,"version":"4.5.1"},"reference-count":60,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T00:00:00Z","timestamp":1626566400000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021058","name":"Project Data Sphere","doi-asserted-by":"crossref","award":["Neurologic irAE Registry with Massachusetts Genera"],"award-info":[{"award-number":["Neurologic irAE Registry with Massachusetts Genera"]}],"id":[{"id":"10.13039\/100021058","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,5,8]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>Expanding the US Food and Drug Administration\u2013approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%\u201312%\u2009and a high fatality rate relative to other irAEs. Lack of standardized disease definitions and accurate phenotyping leads to syndrome misclassification and impedes development of evidence-based treatments and translational research. The objective of this study was to develop consensus guidance for an approach to irAE-Ns including disease definitions and severity grading. A working group of four neurologists drafted irAE-N consensus guidance and definitions, which were reviewed by the multidisciplinary Neuro irAE Disease Definition Panel including oncologists and irAE experts. A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings to discuss areas of controversy. Panelists rated content for usability, appropriateness and accuracy on 9-point scales in electronic surveys and provided free text comments. Aggregated survey responses were incorporated into revised definitions. Consensus was based on numeric ratings using the RAND\/University of California Los Angeles (UCLA) Appropriateness Method with prespecified definitions. 27 panelists from 15 academic medical centers voted on a total of 53 rating scales (6 general guidance, 24 central and 18 peripheral nervous system disease definition components, 3 severity criteria and 2 clinical trial adjudication statements); of these, 77% (41\/53) received first round consensus. After revisions, all items received second round consensus. Consensus definitions were achieved for seven core disorders: irMeningitis, irEncephalitis, irDemyelinating disease, irVasculitis, irNeuropathy, irNeuromuscular junction disorders and irMyopathy. For each disorder, six descriptors of diagnostic components are used: disease subtype, diagnostic certainty, severity, autoantibody association, exacerbation of pre-existing disease or de novo presentation, and presence or absence of concurrent irAE(s). These disease definitions standardize irAE-N classification. Diagnostic certainty is not always directly linked to certainty to treat as an irAE-N (ie, one might treat events in the probable or possible category). Given consensus on accuracy and usability from a representative panel group, we anticipate that the definitions will be used broadly across clinical and research settings.<\/jats:p>","DOI":"10.1136\/jitc-2021-002890","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T10:45:58Z","timestamp":1626691558000},"page":"e002890","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":211,"title":["Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0843-2935","authenticated-orcid":false,"given":"Amanda C","family":"Guidon","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Neuromuscular Medicine, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeann B","family":"Burton","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Neuromuscular Medicine, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart K","family":"Chwalisz","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Neuroimmunology and Neuroinfectious Disease, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hillis","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Neuroimmunology and Neuroinfectious Disease, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teilo H","family":"Schaller","sequence":"additional","affiliation":[{"name":"Project Data Sphere, Cary, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A","family":"Amato","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Neuromuscular Medicine, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6422-2997","authenticated-orcid":false,"given":"Allison","family":"Betof Warner","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla K","family":"Brastianos","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey A","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Neurology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey L","family":"Clardy","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Utah, Salt Lake CIty, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine V","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Pennsylvania, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9266-2009","authenticated-orcid":false,"given":"Michael","family":"Dougan","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T","family":"Doughty","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Neuromuscular Medicine, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M","family":"Gelfand","sequence":"additional","affiliation":[{"name":"Department of Neurology, UCSF, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T","family":"Guptill","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University, Durham, NC, USA"},{"name":"Division of Neuromuscular Medicine, Duke University, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vern C","family":"Juel","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Medicine, Duke University, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kadish","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Utah, Salt Lake CIty, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Kolb","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Medicine, Department of Neurology, University of Vermont, Burlington, VT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R","family":"LeBoeuf","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Dermatology, Center for Cutaneous Oncology, Dana-Farber\/Brigham and Women\u2019s Cancer Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Linnoila","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Neuroimmunology and Neuroinfectious Disease, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L","family":"Mammen","sequence":"additional","affiliation":[{"name":"Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Martinez-Lage","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Neuropathology, Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-8015","authenticated-orcid":false,"given":"Meghan J","family":"Mooradian","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-8686","authenticated-orcid":false,"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Medicine, Beaumont Hospital Dublin and RCSI University of Health Sciences, Dublin, Ireland"},{"name":"Upper Aerodigestive Division, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center\/Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G","family":"Neilan","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Cardio-oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Reardon","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Center for Neuro-oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista M","family":"Rubin","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca D","family":"Santomasso","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Wang","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Woodman","sequence":"additional","affiliation":[{"name":"Section of Cancer Neurology, Department of Neuro-Oncology, MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4226-7443","authenticated-orcid":false,"given":"Leyre","family":"Zubiri","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C","family":"Louv","sequence":"additional","affiliation":[{"name":"Project Data Sphere, Cary, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"2025100305154237000_9.7.e002890.1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","article-title":"Advances in cancer immunotherapy 2019 - latest trends","volume":"38","author":"Kruger","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"2025100305154237000_9.7.e002890.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2025100305154237000_9.7.e002890.3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/d41573-019-00182-w","article-title":"Trends in clinical development for PD-1\/PD-L1 inhibitors","volume":"19","author":"Xin Yu","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2025100305154237000_9.7.e002890.4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"2025100305154237000_9.7.e002890.5","unstructured":"Cancer research Institute Timeline of progress. Available: https:\/\/www.cancerresearch.org\/immunotherapy\/timeline-of-progress"},{"key":"2025100305154237000_9.7.e002890.6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535"},{"key":"2025100305154237000_9.7.e002890.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1091-2"},{"key":"2025100305154237000_9.7.e002890.8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/d41573-019-00167-9","article-title":"Immuno-oncology drug development goes global","volume":"18","author":"Xin Yu","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025100305154237000_9.7.e002890.9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"key":"2025100305154237000_9.7.e002890.10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0359"},{"key":"2025100305154237000_9.7.e002890.11","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.mayocp.2019.03.012","article-title":"Immune checkpoint inhibitor toxicities","volume":"94","author":"Marin-Acevedo","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2025100305154237000_9.7.e002890.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2025100305154237000_9.7.e002890.13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/NRL.0000000000000230","article-title":"Risk of neurological toxicities following the use of different immune checkpoint inhibitor regimens in solid tumors: a systematic review and meta-analysis","volume":"24","author":"Xu","year":"2019","journal-title":"Neurologist"},{"key":"2025100305154237000_9.7.e002890.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.001"},{"key":"2025100305154237000_9.7.e002890.15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/WCO.0000000000000867","article-title":"Central nervous system injury from novel cancer immunotherapies","volume":"33","author":"Winter","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"2025100305154237000_9.7.e002890.16","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025100305154237000_9.7.e002890.17","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"2025100305154237000_9.7.e002890.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100305154237000_9.7.e002890.19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"2025100305154237000_9.7.e002890.20","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0013"},{"key":"2025100305154237000_9.7.e002890.21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"2025100305154237000_9.7.e002890.22","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1002\/cam4.2397","article-title":"Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control","volume":"8","author":"Hughes","year":"2019","journal-title":"Cancer Med"},{"key":"2025100305154237000_9.7.e002890.23","unstructured":"Fitch K , ed. The Rand\/UCLA appropriateness method user\u2019s manual. Santa Monica: Rand, 2001."},{"key":"2025100305154237000_9.7.e002890.24","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x"},{"key":"2025100305154237000_9.7.e002890.25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1055\/s-0036-1585453","article-title":"Autoantibody-Associated central nervous system neurologic disorders","volume":"36","author":"Linnoila","year":"2016","journal-title":"Semin Neurol"},{"key":"2025100305154237000_9.7.e002890.26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/CON.0000000000000487","article-title":"Autoimmune neurology of the central nervous system","volume":"23","author":"Tobin","year":"2017","journal-title":"Continuum"},{"key":"2025100305154237000_9.7.e002890.27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100305154237000_9.7.e002890.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.02.003"},{"key":"2025100305154237000_9.7.e002890.29","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1996.00550070064013"},{"key":"2025100305154237000_9.7.e002890.30","first-page":"1","article-title":"Aseptic meningitis as an immune-related adverse event after pembrolizumab","volume":"2019","author":"Lima","year":"2019","journal-title":"Case Rep Oncol Med"},{"key":"2025100305154237000_9.7.e002890.31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8931"},{"key":"2025100305154237000_9.7.e002890.32","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/neuonc\/noy186","article-title":"Novel methods to diagnose leptomeningeal metastases in breast cancer","volume":"21","author":"Angus","year":"2019","journal-title":"Neuro Oncol"},{"key":"2025100305154237000_9.7.e002890.33","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-019-0859-2","article-title":"Neurologic immune-related adverse events associated with immune checkpoint inhibition","volume":"21","author":"Pan","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"2025100305154237000_9.7.e002890.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.08.007"},{"key":"2025100305154237000_9.7.e002890.35","first-page":"267","article-title":"Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: a case report","volume":"10","author":"Niki","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"2025100305154237000_9.7.e002890.36","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/WCO.0000000000000686","article-title":"Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy","volume":"32","author":"Perrinjaquet","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"2025100305154237000_9.7.e002890.37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"2025100305154237000_9.7.e002890.38","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/WNL.0000000000002594","article-title":"Cns demyelination and enhanced myelin-reactive responses after ipilimumab treatment","volume":"86","author":"Cao","year":"2016","journal-title":"Neurology"},{"key":"2025100305154237000_9.7.e002890.39","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0818-3"},{"key":"2025100305154237000_9.7.e002890.40","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ana.24715","article-title":"Ctla4 as immunological checkpoint in the development of multiple sclerosis","volume":"80","author":"Gerdes","year":"2016","journal-title":"Ann Neurol"},{"key":"2025100305154237000_9.7.e002890.41","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198801000-00002"},{"key":"2025100305154237000_9.7.e002890.42","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418785071","article-title":"Primary angiitis of the central nervous system: diagnosis and treatment","volume":"11","author":"Beuker","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"2025100305154237000_9.7.e002890.43","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2015.4078","article-title":"Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation","volume":"73","author":"Auriel","year":"2016","journal-title":"JAMA Neurol"},{"key":"2025100305154237000_9.7.e002890.44","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715"},{"key":"2025100305154237000_9.7.e002890.45","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025100305154237000_9.7.e002890.46","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A3909"},{"key":"2025100305154237000_9.7.e002890.47","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"key":"2025100305154237000_9.7.e002890.48","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"2025100305154237000_9.7.e002890.49","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1212\/CON.0000000000000807","article-title":"Lambert-Eaton myasthenic syndrome, botulism, and immune checkpoint Inhibitor-Related myasthenia gravis","volume":"25","author":"Guidon","year":"2019","journal-title":"Continuum"},{"key":"2025100305154237000_9.7.e002890.50","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y"},{"key":"2025100305154237000_9.7.e002890.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.049"},{"key":"2025100305154237000_9.7.e002890.52","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"2025100305154237000_9.7.e002890.53","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","article-title":"Inflammatory myopathy associated with PD-1 inhibitors","volume":"100","author":"Seki","year":"2019","journal-title":"J Autoimmun"},{"key":"2025100305154237000_9.7.e002890.54","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000196"},{"key":"2025100305154237000_9.7.e002890.55","doi-asserted-by":"crossref","first-page":"e3002","DOI":"10.1212\/WNL.0000000000010910","article-title":"Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm","volume":"95","author":"Shelly","year":"2020","journal-title":"Neurology"},{"key":"2025100305154237000_9.7.e002890.56","doi-asserted-by":"crossref","first-page":"e1800","DOI":"10.1212\/WNL.0000000000010619","article-title":"Comparison of ice pack test and single-fiber EMG diagnostic accuracy in patients referred for myasthenic ptosis","volume":"95","author":"Giannoccaro","year":"2020","journal-title":"Neurology"},{"key":"2025100305154237000_9.7.e002890.57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2025100305154237000_9.7.e002890.58","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006124"},{"key":"2025100305154237000_9.7.e002890.59","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"key":"2025100305154237000_9.7.e002890.60","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaneurol.2018.2295","article-title":"Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis Consortium consensus group","volume":"75","author":"Stern","year":"2018","journal-title":"JAMA Neurol"}],"updated-by":[{"DOI":"10.1136\/jitc-2021-002890corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-002890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:15:53Z","timestamp":1759493753000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-002890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,19]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/jitc-2021-002890"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-002890","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}